Artiva director gets 13,750 stock options at $10.88

Artiva Biotherapeutics, Inc. (ARTV) reported that director Daniel G. Baker received a stock option award for 13,750 shares of common stock on September 8, 2026.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that director Daniel G. Baker received a stock option award for 13,750 shares of common stock on September 8, 2026. The option has an exercise price of $10.88 per share and expires on September 7, 2036.

The option vests in full on the earlier of September 8, 2027 or the date of Artiva Biotherapeutics’ 2027 annual stockholder meeting, and following this grant Baker holds 13,750 option shares directly.

Insider Trade Summary

Grant/Award: 13,750 shares

Grant/Award 1 txn

Insider Baker Daniel G.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	13,750	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 13,750 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

Key Figures

Option shares granted: 13,750 shares Exercise price: $10.88 per share Shares subject to option after grant: 13,750 shares +2 more

5 metrics

Option shares granted 13,750 shares Director stock option granted to Daniel G. Baker on September 8, 2026

Exercise price $10.88 per share Exercise price of the director stock option

Shares subject to option after grant 13,750 shares Total option shares held directly by Daniel G. Baker following the grant

Vesting date trigger September 8, 2027 Option vests on this date or earlier if the 2027 annual stockholder meeting occurs before

Option expiration date September 7, 2036 Expiration of the director stock option

Key Terms

Director Stock Option, vest in full, annual stockholder meeting

3 terms

Director Stock Option financial

"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."

vest in full financial

"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."

annual stockholder meeting financial

"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARTV report for director Daniel G. Baker?

Artiva Biotherapeutics reported that director Daniel G. Baker received a stock option for 13,750 shares of common stock on September 8, 2026, with an exercise price of $10.88 per share and expiration on September 7, 2036.

What is the vesting schedule of Daniel G. Baker’s new ARTV stock option?

The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of Artiva Biotherapeutics’ 2027 annual stockholder meeting.

How many ARTV shares are covered by Daniel G. Baker’s stock option after this grant?

After this grant, Daniel G. Baker holds stock options covering 13,750 shares of Artiva Biotherapeutics common stock directly.

What is the exercise price and term of Daniel G. Baker’s ARTV option grant?

The stock option granted to Daniel G. Baker has an exercise price of $10.88 per share and expires on September 7, 2036.

Was Daniel G. Baker’s ARTV stock option grant made under a Rule 10b5-1 trading plan?

No. The filing indicates no Rule 10b5-1 trading plan for this option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 05:56 PM EDT Accepted by SEC EDGAR 09/08/2026 - 05:55 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baker Daniel G.

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$10.88	09/08/2026		A		13,750		(1)	09/07/2036	Common Stock	13,750	$0	13,750	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

	/s/ Jennifer Bush, Attorney-in-Fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)